Tsutomu Nakazawa

15PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersInnate immunityMolecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 25, 2026
A Prognostic Model Incorporating Age and Systemic Inflammation Response Index for Primary CNS Lymphoma.

|May 12, 2026
Prognostic Value of EGFR Mutation Subtypes After Linac-Based Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastasis From EGFR-Mutated Non-Small Cell Lung Cancer.

|Nov 11, 2025
Postoperative Seizures Can Predict Overall Survival of Patients With Newly Diagnosed Supratentorial Isocitrate Dehydrogenase-Wild Glioblastoma Treated With Radiotherapy Plus Concomitant and Adjuvant Temozolomide.

Kengo Yamada, Ryosuke Matsuda, Ryota Sasaki

|Jun 19, 2024
Characterization of HIF-1α Knockout Primary Human Natural Killer Cells Including Populations in Allogeneic Glioblastoma.

Tsutomu Nakazawa, Takayuki Morimoto, Ryosuke Maeoka

|Feb 24, 2024
Antitumor Effects of Intravenous Natural Killer Cell Infusion in an Orthotopic Glioblastoma Xenograft Murine Model and Gene Expression Profile Analysis.

Takayuki Morimoto, Tsutomu Nakazawa, Ryosuke Matsuda

|Sep 28, 2023
Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom.

Ryosuke Maeoka, Tsutomu Nakazawa, Ryosuke Matsuda

Pageof 3

Frequent Collaborators

12 joint publications

Ichiro Nakagawa

10 joint publications

Shuichi Yamada

10 joint publications

Ryosuke Matsuda

10 joint publications

Takayuki Morimoto